A four-legged precedent for generic user fees
Discussions between FDA and the Generic Pharmaceutical Association about the creation of a user fee program are on hold, but some generic drug companies are moving forward with another such program - this one for animal products. Led by Ivax's animal health division, the Generic Animal Drug Association has worked out a plan with the administration to add a generic component to the renewal of the animal drug user fee program now working its way through Congress. Whether the program will serve as a guide dog or a canary in the coal mine for the human generic industry remains to be seen
You may also be interested in...
Teva CEO Kåre Schultz believes his prediction is coming true for the Truxima biosimilar in-licensed from Celltrion, as he gave the latest update on Teva’s efforts to settle significant legal issues around the US opioid crisis.
The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.
The UK’s implementation of a new national licensing framework for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as the cause of an indefinite delay in the consultation process.